← All organizations
Highest phase reached
Phase 4
Acquired by Pfizer on May 11, 2022
Timeline
2010s
- Jun 1, 2014
Biohaven Pharmaceuticals Inc.— Founded
2020s
- Feb 27, 2020
rimegepant— Marketing Organization
- Jan 21, 2021
Kleo Pharmaceuticals— Acquired
- May 11, 2022
Pfizer— Acquired By
Drugs by trial phase (21 distinct, 58 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (8 own, 0 via acquisition)
Phase 2 (8 own, 0 via acquisition)
Indications
Studied for
- Alzheimer Disease
- Amyotrophic Lateral Sclerosis
- Anxiety Disorders
- Ataxia
- Atrophy
- Cerebellar Ataxia
- Compulsive Personality Disorder
- Disease
- Hyperacusis
- Hypotension
- Hypotension, Orthostatic
- Machado-Joseph Disease
- Migraine Disorders
- Motor Neuron Disease
- Multiple Myeloma
- Multiple System Atrophy
- Neoplasms, Plasma Cell
- Neuralgia
- Obsessive-Compulsive Disorder
- Phobia, Social
- Photophobia
- Psoriasis
- Sclerosis
- Shy-Drager Syndrome
- Spinocerebellar Ataxias
- Spinocerebellar Degenerations
- Trigeminal Neuralgia
Marketed drugs (1)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (50)
- NCT03537807Lead sponsorN/A—
- NCT03934086Lead sponsorN/A—
- NCT05086094Lead sponsorN/A—
- NCT06034886Lead sponsorN/A—
- NCT07262268Lead sponsorPhase 1Dec 31, 2025
- NCT07281495Lead sponsorPhase 2Nov 24, 2025
- NCT07125261CollaboratorPhase 1Oct 7, 2025
- NCT06980649Lead sponsorPhase 1Aug 21, 2025
- NCT07054684Lead sponsorPhase 1Jul 30, 2025
- NCT06976268Lead sponsorPhase 2/Phase 3May 28, 2025
- NCT06874335Lead sponsorPhase 1Mar 20, 2025
- NCT06552260CollaboratorEarly Phase 1Feb 28, 2025
- NCT06603623Lead sponsorPhase 2Oct 10, 2024
- NCT06423781Lead sponsorPhase 2Aug 1, 2024
- NCT06443463Lead sponsorPhase 2Jul 30, 2024
Details
- Founded
- New Haven, CT, US Jun 1, 2014
- Last known activity
- Dec 31, 2025